Refine
Has Fulltext
- yes (14)
Is part of the Bibliography
- yes (14)
Year of publication
Document Type
- Journal article (12)
- Report (2)
Keywords
- IGRT (2)
- inflammation (2)
- 5-fluorouracil (1)
- ALS (1)
- ARIA (1)
- Audiologie (1)
- CARAT (1)
- Caco2 cells (1)
- Chirurgie (1)
- Chlamydia (1)
- Chlamydia trachomatis (1)
- Claudin2 (1)
- Diagnostik (1)
- Dsg2 (1)
- HUWE1 (1)
- Halcyon (1)
- Hörgeräte (1)
- III secretion system (1)
- Kategorienskalierung (1)
- Legionella (1)
- MASK (1)
- MIZ1 (1)
- MYC (1)
- Mycobacterium (1)
- Mycobacterium tuberculosis (1)
- PI-3-kinase (1)
- PPAR-gamme (1)
- Pathogens (1)
- SOD1 mutations (1)
- Salmonella (1)
- Schwerhörigkeit (1)
- Simkania (1)
- Simkania negevensis (1)
- Strahlentherapie (1)
- Toll-like receptors (1)
- asthma (1)
- bacterium Legionella pneumophila (1)
- cancer (1)
- central nervous system (1)
- chemotherapy (1)
- colorectal cancer (1)
- colorectal carcinoma (1)
- cone beam CT (1)
- delays progression (1)
- desmosome (1)
- digestive system (1)
- digital transformation of health and care (1)
- disease progression (1)
- dose to OARs (1)
- drug discovery (1)
- endocytic multivesicular bodies (1)
- endoplasmic reticulum (1)
- enteroids (1)
- globale Sprachverständlichkeit (1)
- gut barrier (1)
- hexanucleotide repeat (1)
- host pathogen interactions (1)
- immuno-magnetic purification (1)
- inflammatory bowel disease (1)
- inflammatory cell model (1)
- intestinal barrier (1)
- intestinal epithelial barrier (1)
- intestinal organoids (1)
- intracellular bacteria (1)
- monocycline (1)
- nonalcoholic steatohepatitis (1)
- oxaliplatin (1)
- pathogen vacuole (1)
- phagosome maturation arrest (1)
- pharmacology (1)
- prostate cancer (1)
- reactivating p53 and inducing tumor apoptosis (RITA) (1)
- rhinitis (1)
- setup verification (1)
- spectrometry-based proteomics (1)
- tight junction (1)
- transgenic mouse model (1)
- transperineal ultrasound (1)
- ubiquitination (1)
- whole breast irradiation (1)
Institute
- Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (4)
- Theodor-Boveri-Institut für Biowissenschaften (4)
- Klinik und Poliklinik für Strahlentherapie (3)
- Institut für Psychologie (bis Sept. 2007) (2)
- Frauenklinik und Poliklinik (1)
- Institut für Anatomie und Zellbiologie (1)
- Institut für Klinische Epidemiologie und Biometrie (1)
- Institut für Molekulare Infektionsbiologie (1)
- Neurologische Klinik und Poliklinik (1)
EU-Project number / Contract (GA) number
- 101042738 (1)
Colorectal carcinoma (CRC) is the most common cancer of the gastrointestinal tract with frequently dysregulated intracellular signaling pathways, including p53 signaling. The mainstay of chemotherapy treatment of CRC is 5-fluorouracil (5FU) and oxaliplatin. The two anticancer drugs mediate their therapeutic effect via DNA damage-triggered signaling. The small molecule reactivating p53 and inducing tumor apoptosis (RITA) is described as an activator of wild-type and reactivator of mutant p53 function, resulting in elevated levels of p53 protein, cell growth arrest, and cell death. Additionally, it has been shown that RITA can induce DNA damage signaling. It is expected that the therapeutic benefits of 5FU and oxaliplatin can be increased by enhancing DNA damage signaling pathways. Therefore, we highlighted the antiproliferative response of RITA alone and in combination with 5FU or oxaliplatin in human CRC cells. A panel of long-term established CRC cell lines (n = 9) including p53 wild-type, p53 mutant, and p53 null and primary patient-derived, low-passage cell lines (n = 5) with different p53 protein status were used for this study. A substantial number of CRC cells with pronounced sensitivity to RITA (IC\(_{50}\)< 3.0 μmol/l) were identified within established (4/9) and primary patient-derived (2/5) CRC cell lines harboring wild-type or mutant p53 protein. Sensitivity to RITA appeared independent of p53 status and was associated with an increase in antiproliferative response to 5FU and oxaliplatin, a transcriptional increase of p53 targets p21 and NOXA, and a decrease in MYC mRNA. The effect of RITA as an inducer of DNA damage was shown by a strong elevation of phosphorylated histone variant H2A.X, which was restricted to RITA-sensitive cells. Our data underline the primary effect of RITA, inducing DNA damage, and demonstrate the differential antiproliferative effect of RITA to CRC cells independent of p53 protein status. We found a substantial number of RITA-sensitive CRC cells within both panels of established CRC cell lines and primary patient-derived CRC cell lines (6/14) that provide a rationale for combining RITA with 5FU or oxaliplatin to enhance the antiproliferative response to both chemotherapeutic agents.
Background
To implement a tangential treatment technique for whole breast irradiation using the Varian Halcyon and to compare it with Elekta Synergy Agility plans.
Methods
For 20 patients two comparable treatment plans with respect to dose coverage and normal tissue sparing were generated. Tangential field-in-field treatment plans (Pinnacle/Synergy) were replanned using the sliding window technique (Eclipse/Halcyon). Plan specific QA was performed using the portal Dosimetry and the ArcCHECK phantom. Imaging and treatment dose were evaluated for treatment delivery on both systems using a modified CIRS Phantom.
Results
The mean number of monitor units for a fraction dose of 2.67 Gy was 515 MUs and 260 MUs for Halcyon and Synergy Agility plans, respectively. The homogeneity index and dose coverage were similar for both treatment units. The plan specific QA showed good agreement between measured and calculated plans. All Halcyon plans passed portal dosimetry QA (3%/2 mm) with 100% points passing and ArcCheck QA (3%/2 mm) with 99.5%. Measurement of the cumulated treatment and imaging dose with the CIRS phantom resulted in lower dose to the contralateral breast for the Halcyon plans.
Conclusions
For the Varian Halcyon a plan quality similar to the Elekta Synergy device was achieved. For the Halcyon plans the dose contribution from the treatment fields to the contralateral breast was even lower due to less interleaf transmission of the Halcyon MLC and a lower contribution of scattered dose from the collimator system.
Sepsis caused by Gram-positive bacterial pathogens is a major fatal disease but its molecular basis remains elusive. Toll-like receptor 2 (TLR2) has been implicated in the orchestration of inflammation and sepsis but its role appears to vary for different pathogen species and clones. Accordingly, Staphylococcus aureus clinical isolates differ substantially in their capacity to activate TLR2. Here we show that strong TLR2 stimulation depends on high-level production of phenol-soluble modulin (PSM) peptides in response to the global virulence activator Agr. PSMs are required for mobilizing lipoproteins, the TLR2 agonists, from the staphylococcal cytoplasmic membrane. Notably, the course of sepsis caused by PSM-deficient S. aureus is similar in wild-type and TLR2-deficient mice, but TLR2 is required for protection of mice against PSM-producing S. aureus. Thus, a crucial role of TLR2 depends on agonist release by bacterial surfactants. Modulation of this process may lead to new therapeutic strategies against Gram-positive infections.
Desmoglein2 Regulates Claudin2 Expression by Sequestering PI-3-Kinase in Intestinal Epithelial Cells
(2021)
Inflammation-induced reduction of intestinal desmosomal cadherin Desmoglein 2 (Dsg2) is linked to changes of tight junctions (TJ) leading to impaired intestinal epithelial barrier (IEB) function by undefined mechanisms. We characterized the interplay between loss of Dsg2 and upregulation of pore-forming TJ protein Claudin2. Intraperitoneal application of Dsg2-stablising Tandem peptide (TP) attenuated impaired IEB function, reduction of Dsg2 and increased Claudin2 in DSS-induced colitis in C57Bl/6 mice. TP blocked loss of Dsg2-mediated adhesion and upregulation of Claudin2 in Caco2 cells challenged with TNFα. In Dsg2-deficient Caco2 cells basal expression of Claudin2 was increased which was paralleled by reduced transepithelial electrical resistance and by augmented phosphorylation of AKT\(^{Ser473}\) under basal conditions. Inhibition of phosphoinositid-3-kinase proved that PI-3-kinase/AKT-signaling is critical to upregulate Claudin2. In immunostaining PI-3-kinase dissociated from Dsg2 under inflammatory conditions. Immunoprecipitations and proximity ligation assays confirmed a direct interaction of Dsg2 and PI-3-kinase which was abrogated following TNFα application. In summary, Dsg2 regulates Claudin2 expression by sequestering PI-3-kinase to the cell borders in intestinal epithelium.